PCRX Pacira Corp: Enterprise Value to EBITDA Ratio
Optimized supply chains for non-opioid agents are driving growth, and the historical EV/EBITDA value on GURU.Markets reflects this trend, where the value 13.26 characterizes this level. The fundamentals of Pacira BioSciences (PCRX) are based on transparent sales management of anesthetics amid patent risks, as well as partnerships with clinics to implement painless patient recovery methodologies.
Comprehensive metric breakdowns and analytics for pacira.com (PCRX)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity Pacira BioSciences|PCRX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Pacira BioSciences, Inc.|PCRX - Company Aggregate Indebtedness|Debts to Book Capitalization Pacira Corp|PCRX - Company Long-Term Debts|Company Short-Term Debts Pacira BioSciences|Quick Ratio pacira.com
- financial results and valuation multiples details:
PCRX - Net Financial Result|Expected Profit Pacira BioSciences|PCRX - Company Value to Net Income|Forward P/E Multiple Pacira BioSciences|PCRX - PEG Multiple|Enterprise Value to EBITDA Ratio Pacira Corp|PCRX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Pacira BioSciences|PCRX - Earnings per share for the last twelve months|Quarterly EPS earnings growth pacira.com|PCRX - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Pacira BioSciences
Fundamental valuation:Pacira PCRX
The EV/EBITDA multiple compares the total enterprise value, including net debt, with operating profit before taxes and amortization, revealing the actual market price of assets. By analyzing the current EV/EBITDA value of Pacira BioSciences (PCRX), an investor can assess the scaling efficiency of non-opioid analgesics, where low production costs coupled with growing sales should ensure high fundamental stability.
Competitors of Pacira BioSciences
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ANI Pharmaceuticals, Inc. ANIP|MNKD (MannKind Corp) - Company Value to Operating Income Before Depreciation Ratio|Amphastar - EV/EBITDA Multiple|SPRY - EV/EBITDA Multiple|TBPH: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio aquestive.com|SCPH (scPharmaceuticals, Inc.) - EV/EBITDA Multiple|Tectonic (TECX) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tonix Pharmaceuticals Inc. (TNXP)|SXTC (sxtchina.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple EPRX (Eupraxia Pharmaceuticals Inc.)|EV/EBITDA Multiple bioharvest.com BHST|EXOZ: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ORMP (Oramed Pharmaceuticals)|ENTX: EV/EBITDA Multiple|HYFT (MindWalk Therapeutics) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ABVC (ABVC BioPharma) - EV/EBITDA Multiple|cumberlandpharma.com (CPIX) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Quantum BioPharma (QNTM)|FGEN - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Telomir Pharma TELO|Total Company Value to Operating Income Before Depreciation Ratio Rani Therapeutics Holdings (RANI)|Synergy CHC Corporation - EV/EBITDA Multiple|Rallybio Corporation (RLYB) - Enterprise Value to EBITDA Ratio|LEXX: EV/EBITDA Multiple|PULM - Total Company Value to Operating Income Before Depreciation Ratio|PTHL (Pheton Holdings Limited) - EV/EBITDA Multiple|Company Value to EBITDA Aptorum APM|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lyra Therapeutics, Inc. (LYRA)|impactbiomedinc.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple TNFA (TNF Pharmaceuticals, Inc.)|YCBD - Enterprise Value to EBITDA Ratio|PainReform Limited - EV/EBITDA Multiple|Company Value to EBITDA Altamira Therapeutics|Lipella Pharmaceuticals (LIPO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|OPTN - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pieris Pharmaceuticals, Inc.|Procaps Group - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PTPI|Enterprise Value to EBITDA Ratio Qilian International Corp QLI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Acelyrin, Inc. SLRN|Business Value to Operating Income Before Depreciation TFFP
